Short answer
CERUS CORP (CERS) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 provides liability protection for the disclosed information under Sections 18, 11, and 12(a)(2).
CERUS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 provides liability protection for the disclosed information under Sections 18, 11, and 12(a)(2)
- Exhibit information not incorporated into other SEC filings unless expressly referenced
- No operating results or financial metrics included in the provided text
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 revenue $59.9M, up 23%; product revenue $53.7M, up 24%, led by platelet products and IFC demand
- IFC demand surged approximately 120%; U.S. IFC sales reached $5.7M versus $3.0M prior year
- Product gross margin fell to 52.0% from 58.8% due to inflation, foreign exchange, tariffs, and a prior-year one-time benefit
- Net loss narrowed to $1.6M from $7.7M; adjusted EBITDA improved to $4.0M from $0.2M
- Product revenue guidance raised to $227M-$231M, including IFC revenue of $22M-$24M; CEO transition effective July 1, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CERUS CORP 8-K filings
Get the next CERS 8-K as it lands
Follow CERS for push alerts, or ask the research agent what this filing means.